These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Aluminium encephalopathy: a potential risk of aluminium gels in children with chronic renal failure. Pillion G; Loirat C; Blum C; Poisson M; Bacri JL; Broyer M; Mathieu H Int J Pediatr Nephrol; 1981 Mar; 2(1):29-32. PubMed ID: 7333766 [No Abstract] [Full Text] [Related]
4. [Current concepts of the role of aluminum in chronic kidney failure patients]. Gruev I; Belovezhdov N Vutr Boles; 1983; 22(2):1-4. PubMed ID: 6362201 [No Abstract] [Full Text] [Related]
5. Calcium carbonate can enhance aluminium absorption from aluminium hydroxide in patients with impaired renal function. Lin JL; Leu ML Nephrol Dial Transplant; 1996 Sep; 11(9):1891-3. PubMed ID: 8918652 [No Abstract] [Full Text] [Related]
6. The fatal interplay of aluminum and citrate in chronic renal failure: a lesson from three decades ago. Bakir AA Artif Organs; 2015 Feb; 39(2):87-9. PubMed ID: 25683287 [No Abstract] [Full Text] [Related]
7. The effect of aluminium hydroxide orally on calcium, phosphorus and aluminium metabolism in normal subjects. Cam JM; Luck VA; Eastwood JB; de Wardener HE Clin Sci Mol Med; 1976 Oct; 51(4):407-14. PubMed ID: 971581 [TBL] [Abstract][Full Text] [Related]
8. Bone aluminum deposition in maintenance dialysis patients treated with aluminium-free dialysate: role of aluminium hydroxide consumption. Heaf JG; Pødenphant J; Andersen JR Nephron; 1986; 42(3):210-6. PubMed ID: 3945361 [TBL] [Abstract][Full Text] [Related]
9. Epidemiology of aluminium toxicity in a 'low incidence' area. Winney RJ; Cowie JF; Cumming AD; Short AI; Smith GD; Robson JS Contrib Nephrol; 1984; 38():47-58. PubMed ID: 6713900 [No Abstract] [Full Text] [Related]
10. Diagnosis and treatment of aluminium overload in end-stage renal failure patients. Nephrol Dial Transplant; 1993; 8 Suppl 1():1-4. PubMed ID: 8389013 [No Abstract] [Full Text] [Related]
11. Risk factors in aluminum toxicity in children with chronic renal failure. Santos F; Massie MD; Chan JC Nephron; 1986; 42(3):189-95. PubMed ID: 3511396 [No Abstract] [Full Text] [Related]
12. What treatment would you advise for a 1-year-old child with chronic renal failure who has been on aluminum hydroxide as a phosphate binder for 6 months and then develops epilepsy and is found to have a grossly raised plasma aluminum concentration? Andreoli SP; Chesney RW; Salusky IB; Sedman AB Pediatr Nephrol; 1990 Jul; 4(4):318. PubMed ID: 2206897 [No Abstract] [Full Text] [Related]
13. Diagnosis and treatment of aluminium overload in end-stage renal failure patients. Consensus conference. Paris, France, 27 June 1992. Nephrol Dial Transplant; 1993; 8 Suppl 1():1-54. PubMed ID: 8389014 [No Abstract] [Full Text] [Related]
14. The dialysis dementia syndrome and aluminum intoxication. Sideman S; Manor D Nephron; 1982; 31(1):1-10. PubMed ID: 7110469 [No Abstract] [Full Text] [Related]
15. The use of desferrioximine in dialysis-associated aluminium disease. Ackrill P; Day JP Contrib Nephrol; 1993; 102():125-34. PubMed ID: 8416177 [No Abstract] [Full Text] [Related]
16. Can low-dosage aluminium hydroxide control the plasma phosphate without bone toxicity? Jenkins DA; Gouldesbrough D; Smith GD; Cowie JF; Winney RJ Nephrol Dial Transplant; 1989; 4(1):51-6. PubMed ID: 2494599 [TBL] [Abstract][Full Text] [Related]
17. The effect of oral aluminium therapy on plasma aluminium levels in patients with chronic renal failure in an area with low water aluminium. Fleming LW; Stewart Wk; Fell GS; Halls DJ Clin Nephrol; 1982 May; 17(5):222-7. PubMed ID: 7094439 [TBL] [Abstract][Full Text] [Related]
18. Dementia, renal failure, and brain aluminum. Arieff AI; Cooper JD; Armstrong D; Lazarowitz VC Ann Intern Med; 1979 May; 90(5):741-7. PubMed ID: 434672 [TBL] [Abstract][Full Text] [Related]